# OnCo record mmae (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/mmae/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "mmae" ;
  schema:name "MMAE"@en ;
  schema:alternateName "monomethyl auristatin E"@en, "vedotin payload"@en, "monomethyl auristatin E, vedotin"@en ;
  schema:description "MMAE is the tubulin-blocking payload in brentuximab, enfortumab, polatuzumab and tisotumab vedotin, four approved ADCs: it halts cell division and, being membrane permeable, leaks into neighbouring tumour cells. Nerve damage and low neutrophil counts are its signature side effects."@en ;
  schema:url <https://onco.cc/terms/mmae/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Monomethyl_auristatin_E> ;
  owl:sameAs <http://www.wikidata.org/entity/Q6901739> ;
  schema:citation <https://en.wikipedia.org/wiki/Monomethyl_auristatin_E> ;
  onco:related <https://onco.cc/terms/efflux-pump/>, <https://onco.cc/terms/bystander-effect/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/enfortumab-vedotin/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/tisotumab-vedotin/>, <https://onco.cc/drugs/telisotuzumab-vedotin/>, <https://onco.cc/drugs/disitamab-vedotin/>, <https://onco.cc/drugs/zilovertamab-vedotin/>, <https://onco.cc/drugs/cmg901/> ;
  onco:terms <https://onco.cc/terms/payload/>, <https://onco.cc/terms/tubulin-inhibitor-payloads/> .